13G Filing: Davidson Kempner Partners and Leisure Acquisition Corp. (LACQU)

Leisure Acquisition Corp. (NASDAQ:LACQU): Thomas Lenox Kempner, Jr.’s Davidson Kempner Partners filed an amended 13D.

You can check out Davidson Kempner Partners’ latest holdings and filings here.

Please follow Davidson Kempner Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Davidson Kempner Partners or update its stock holdings.

Follow Thomas Lenox Kempner And Anthony Yoseloff's Davidson Kempner

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Davidson Kempner Partners 0 272,850 0 272,850 272,850 1.06%
Davidson Kempner Institutional Partners 0 578,850 0 578,850 578,850 2.25%
Davidson Kempner International, Ltd 0 648,300 0 648,300 648,300 2.52%
Davidson Kempner Capital Management 0 1,500,000 0 1,500,000 1,500,000 5.83%
Thomas L. Kempner, Jr 0 1,500,000 0 1,500,000 1,500,000 5.83%
Robert J. Brivio, Jr 0 1,500,000 0 1,500,000 1,500,000 5.83%

Page 1 of 12 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*

Leisure Acquisition
Corp.

(Name of Issuer)

Common Stock,
par value $0.0001 per share

(Title of Class of Securities)

52539T206**

(CUSIP Number)

December
1, 2017

(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
ý Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 12 Pages)

______________________________

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**The Common Stock has no CUSIP number.
The CUSIP number for the units which include the Common Stock is 52539T206.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act“) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Ensysce Biosciences Inc.

Page 2 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Davidson Kempner Partners

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

272,850

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

272,850

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

272,850

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.06%

12

TYPE OF REPORTING PERSON

PN

Follow Ensysce Biosciences Inc.

Page 3 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Davidson Kempner Institutional Partners, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

578,850

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

578,850

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

578,850

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.25%

12

TYPE OF REPORTING PERSON

PN

Follow Ensysce Biosciences Inc.

Page 4 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Davidson Kempner International, Ltd.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

648,300

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

648,300

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

648,300

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.52%

12

TYPE OF REPORTING PERSON

CO

Follow Ensysce Biosciences Inc.

Page 5 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Davidson Kempner Capital Management LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

1,500,000

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

1,500,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.83%

12

TYPE OF REPORTING PERSON

PN

 

Follow Ensysce Biosciences Inc.

Page 6 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Thomas L. Kempner, Jr.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

1,500,000

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

1,500,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.83%

12

TYPE OF REPORTING PERSON

IN

Follow Ensysce Biosciences Inc.

Page 7 of 12 – SEC Filing

1

NAME OF REPORTING PERSON

Robert J. Brivio, Jr.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ý

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

1,500,000

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

1,500,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,500,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.83%

12

TYPE OF REPORTING PERSON

IN

Follow Ensysce Biosciences Inc.

Page 8 of 12 – SEC Filing

Item 1(a). NAME OF ISSUER
Leisure Acquisition Corp. (the “Issuer“)
Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
250 West 57th Street, Suite 2223, New York, New York 10107
Item 2(a). NAME OF PERSON FILING
This Statement is filed by each of the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons“:
(i) Davidson Kempner Partners, a New York limited partnership (“DKP“). MHD Management Co., a New York limited partnership (“MHD“), is the general partner of DKP and MHD Management Co. GP, L.L.C., a Delaware limited liability company, is the general partner of MHD.  DKCM is responsible for the voting and investment decisions of DKP;
(ii) Davidson Kempner Institutional Partners, L.P., a Delaware limited partnership (“DKIP“). Davidson Kempner Advisers Inc., a New York corporation, is the general partner of DKIP. DKCM is responsible for the voting and investment decisions of DKIP;
(iii) Davidson Kempner International, Ltd., a British Virgin Islands business company (“DKIL“).  DKCM is the investment manager of DKIL and is responsible for the voting and investment decisions of DKIL;
(iv) Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission, acts as investment manager to each of DKP, DKIP and DKIL (“DKCM“). DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM.  The managing members of DKCM are Thomas L. Kempner, Jr., Robert J. Brivio, Jr., Eric P. Epstein, Anthony A. Yoseloff, Avram Z. Friedman, Conor Bastable, Morgan P. Blackwell, Shulamit Leviant, Patrick W. Dennis and Gabriel T. Schwartz; and
(v) Messrs. Thomas L. Kempner, Jr. and Robert J. Brivio, Jr. through DKCM, are responsible for the voting and investment decisions relating to the securities held by DKP, DKIP and DKIL reported herein.
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
The address of the principal business office of each of the Reporting Persons is c/o Davidson Kempner Capital Management LP, 520 Madison Avenue, 30th Floor, New York, New York 10022.

Follow Ensysce Biosciences Inc.

Page 9 of 12 – SEC Filing

Item 2(c). CITIZENSHIP
(i) DKP – a New York limited partnership
(ii) DKIP – a Delaware limited partnership
(iii) DKIL – a British Virgin Islands business company
(iv) DKCM – a Delaware limited partnership
(v) Messrs. Thomas L. Kempner, Jr. and Robert J. Brivio, Jr. – United States
Item 2(d). TITLE OF CLASS OF SECURITIES
Common Stock, par value $0.0001 per share (the “Common Stock“)
Item 2(e). CUSIP NUMBER
The Common Stock has no CUSIP number. The CUSIP number for the units which include the Common Stock is 52539T206.
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) ¨ Broker or dealer registered under Section 15 of the Act;
(b) ¨ Bank as defined in Section 3(a)(6) of the Act;
(c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
(d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
(e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) ¨

An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);

(g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
(h) ¨

A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;

(i) ¨

A church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of the Investment Company Act;

Follow Ensysce Biosciences Inc.

Page 10 of 12 – SEC Filing

(j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in
accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________________________________
Item 4. OWNERSHIP.
The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
The percentages used in this Schedule 13G are calculated based upon the 25,750,000 shares of Common Stock reported to be outstanding in the Issuer’s Prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission on December 1, 2017 after giving effect to the completion of the offering, as described therein.
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
Not applicable.
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
Item 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
Item 10. CERTIFICATION
Each of the Reporting Persons hereby makes the following certification:
By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Ensysce Biosciences Inc.

Page 11 of 12 – SEC Filing

SIGNATURES

After reasonable
inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.

DATE: December 11, 2017

davidson kempner partners
By:  MHD Management Co.,
its General Partner
By:  MHD Management Co. GP, L.L.C.,
its General Partner
/s/ Thomas L. Kempner, Jr.
Name: Thomas L. Kempner, Jr.
Title: Executive Managing Member
DAVIDSON KEMPNER institutional partners, L.P.
By: Davidson Kempner Advisers Inc.,
its General Partner
/s/ Thomas L. Kempner, Jr.
Name: Thomas L. Kempner, Jr.
Title: President
davidson kempner international, ltd.
By:  Davidson Kempner Capital Management LP,
its Investment Manager
/s/ Thomas L. Kempner, Jr.
Name: Thomas L. Kempner, Jr.
Title: Executive Managing Member
davidson kempner CAPITAL MANAGEMENT LP
/s/ Thomas L. Kempner, Jr.
Name:  Thomas L. Kempner, Jr.
Title:    Executive Managing Member
/s/ Thomas L. Kempner, Jr.
THOMAS L. KEMPNER, JR.
/s/ Robert J. Brivio, Jr.
ROBERT J. BRIVIO, JR.

Follow Ensysce Biosciences Inc.

Page 12 of 12 – SEC Filing

JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge
and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments
to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional
joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and
for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason
to believe that such information is inaccurate.

DATE:
December 11, 2017

davidson kempner partners
By: MHD Management Co.,
its General Partner
By: MHD Management Co. GP, L.L.C.,
its General Partner
/s/ Thomas L. Kempner, Jr.
Name:  Thomas L. Kempner, Jr.
Title:    Executive Managing Member
DAVIDSON KEMPNER institutional partners, L.P.
By: Davidson Kempner Advisers Inc.,
its General Partner
/s/ Thomas L. Kempner, Jr.
Name:  Thomas L. Kempner, Jr.
Title:    President
davidson kempner international, ltd.
By: Davidson Kempner Capital Management LP,
its Investment Manager
/s/ Thomas L. Kempner, Jr.
Name:  Thomas L. Kempner, Jr.
Title:    Executive Managing Member
davidson kempner CAPITAL MANAGEMENT LP
/s/ Thomas L. Kempner, Jr.
Name:  Thomas L. Kempner, Jr.
Title:    Executive Managing Member
/s/ Thomas L. Kempner, Jr.
THOMAS L. KEMPNER, JR.
/s/  Robert J. Brivio, Jr.
ROBERT J. BRIVIO, JR.

Follow Ensysce Biosciences Inc.